Ghana Vaccine Survey Shows 90% Public Confidence, Strong Backing for ‘Made-in-Ghana’ Shots Ahead of 2027 Launch

Ghanaians overwhelmingly trust vaccines and are ready to support locally manufactured doses once production begins in 2027, according to a new national survey released by the National Vaccine Institute (NVI).

The Vaccine Perception Survey, conducted across all 16 regions and 55 districts, analyzed 13,905 valid responses to gauge public attitudes toward vaccines, locally produced health products, and the country’s plan to start vaccine manufacturing. The findings challenge the narrative of widespread vaccine hesitancy and provide a roadmap for public education ahead of Ghana’s entry into vaccine production.

High Confidence, High Responsibility

The results show strong nationwide confidence in vaccines. About *89.7% of respondents expressed confidence in vaccines*, while *94.2% said they feel a collective responsibility to ensure vaccines remain available* in the country.

Willingness to accept Ghana-made vaccines is also high. *71.3% of respondents said they would accept and use vaccines manufactured in Ghana*, indicating that more than seven out of ten Ghanaians are prepared to embrace the “Made-in-Ghana” agenda.

Trust in the health system emerged as a key driver. *87.8% of respondents said they trust doctors and nurses who administer vaccines*, and many also expressed confidence in the Ghana Health Service (GHS) and the Food and Drugs Authority (FDA).

“This strong institutional trust provides a solid foundation for Ghana’s vaccine manufacturing agenda and positions healthcare workers as key advocates in building public confidence in locally produced vaccines,” the NVI said.

Awareness Gap on Local Manufacturing

Despite the positive outlook, the survey found a major awareness gap. Only *14.3% of respondents knew that Ghana is building local vaccine manufacturing capacity* ahead of the planned 2027 launch.

The NVI said the finding highlights an urgent need for a nationwide awareness campaign to educate the public, counter misinformation, and build ownership of the initiative.

The survey also revealed regional differences in vaccine acceptance. Urbanized regions such as Greater Accra, Central, and Ashanti recorded comparatively lower acceptance despite better access to information. By contrast, rural communities in northern Ghana and regions like Oti showed stronger trust and acceptance. The NVI said the variation points to the need for targeted, context-specific communication strategies.

National Pride Meets Practical Concerns

Respondents expressed strong national pride in the idea of Ghanaian scientists and local factories producing vaccines. Many said seeing local involvement would increase their confidence in Ghana-made products.

However, the study flagged several barriers that could affect uptake. These include the cost of vaccines, distance to vaccination centers, and concerns about storage and transportation systems. Cold chain infrastructure in rural areas was singled out as a particular concern that could undermine confidence at the point of delivery.

To address this, the NVI said it and other stakeholders must strengthen cold chain systems, improve storage and transport, and ensure transparent handling protocols to maintain public trust.

Nationwide Campaign Planned Ahead of 2027 Launch

As Ghana prepares to launch locally manufactured vaccines in 2027, the NVI announced plans for a nationwide awareness and acceptance campaign. The campaign will educate the public on locally produced vaccines, address misinformation, and promote national buy-in.

The effort will involve government institutions, development partners, healthcare professionals, civil society organizations, community leaders, the private sector, and the media.

“Ghana has a strong foundation of vaccine confidence, but success depends on bridging the awareness and trust gap for locally manufactured vaccines,” said *Dr. Sodzi Sodzi-Tettey*, Chief Executive Officer of the NVI. “What is needed now is targeted policy and communication strategies to address misinformation, cost barriers, and regional disparities in order to encourage uptake. NVI is indebted to the GHS, FDA, and the WHO for their continuous support and valuable insights they bring to the Institute’s work.”

Why It Matters for Ghana and Africa

Public perception remains one of the most important factors in vaccine uptake. The survey provides baseline data to help government and health partners design behavior-change interventions, prepare messaging strategies, and anticipate misinformation narratives.

The timing is critical. Ghana’s pharmaceutical sector is transitioning toward vaccine self-sufficiency, with locally manufactured vaccines expected to be launched in 2027. The move is a major step in the country’s pharmaceutical innovation, industrial growth, and health security agenda.

It also aligns with the African Union’s Partnerships for African Vaccine Manufacturing (PAVM), which aims for Africa to produce at least 60% of its vaccines by 2040. If successful, Ghana’s initiative could serve as a model for other African countries seeking to reduce dependence on imported vaccines.

A Historic Turning Point

The NVI said the survey sends a clear message: Ghanaians believe in vaccines and are prepared to support the country’s journey toward vaccine self-sufficiency.

“While awareness of the local manufacturing agenda remains low, the high levels of public trust in healthcare professionals, regulatory institutions, and the national health system provide a powerful foundation for success,” the institute stated.

Ghana now stands at what the NVI called “a historic turning point” in public health and industrial development. The planned production of locally manufactured vaccines in 2027 is about more than health security. It is also about national pride, scientific advancement, economic resilience, and Africa’s determination to control its health future.

With sustained public education, stakeholder collaboration, transparent regulation, and national commitment, the NVI said Ghana has the opportunity to become a leading example of vaccine confidence and local pharmaceutical innovation on the continent.